Cited by 220Nanoparticle-Based Drug DeliveryNanoplatforms for cancer theranosticsMesoporous Materials and Catalysis

Lectin-conjugated pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment

Open access
Martínez-Carmona, Marina, Lozano, Daniel, Colilla, Montserrat, Vallet-Regí, María·2018·Acta Biomaterialia

Abstract

A novel multifunctional nanodevice based in doxorubicin (DOX)-loaded mesoporous silica nanoparticles (MSNs) as nanoplatforms for the assembly of different building blocks has been developed for bone cancer treatment. These building blocks consists of: i) a polyacrylic acid (PAA) capping layer grafted to MSNs via an acid-cleavable acetal linker, to minimize premature cargo release and provide the nanosystem of pH-responsive drug delivery ability; and ii) a targeting ligand, the plant lectin concanavalin A (ConA), able to selectively recognize, bind and internalize owing to certain cell-surface glycans, such as sialic acids (SA), overexpressed in given tumor cells. This multifunctional nanosystem exhibits a noticeable higher internalization degree into human osteosarcoma cells (HOS), overexpressing SA, compared to healthy preosteoblast cells (MC3T3-E1). Moreover, the results indicate that small DOX loading (2.5 µg mL-1) leads to almost 100% of osteosarcoma cell death in comparison with healthy bone cells, which significantly preserve their viability. Besides, this nanodevice has a cytotoxicity on tumor cells 8-fold higher than that caused by the free drug. These findings demonstrate that the synergistic combination of different building blocks into a unique nanoplatform increases antitumor effectiveness and decreases toxicity towards normal cells. This line of attack opens up new insights in targeted bone cancer therapy.Statement of significance The development of highly selective and efficient tumor-targeted smart drug delivery nanodevices remains a great challenge in nanomedicine. This work reports the design and optimization of a multifunctional nanosystem based on mesoporous silica nanoparticles (MSNs) featuring selectivity towards human osteosarcoma cells and pH-responsive antitumor drug delivery capability. The novelty and originality of this manuscript relies on proving that the synergistic assembly of different building blocks into a unique nanoplatform increases antitumor effectiveness and decreases toxicity towards healthy cells, which constitutes a new paradigm in targeted bone cancer therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.actbio.2017.11.007

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Martínez-Carmona, M., Lozano, D., Colilla, M., & Vallet-Regí, M.
Affiliations
Universidad Complutense de Madrid (ES)
Corresponding author
Colilla, Montserrat
Venue
Acta Biomaterialia
Publisher
Elsevier BV
Published
2018-01
Volume
65
Pages
393-404
ISSN
1742-7061 (ISSN-L)
OpenAlex
W2767616074
Cited by
220
References
83
Citations by year
2026: 16 · 2025: 23 · 2024: 14 · 2023: 23 · 2022: 33 · 2021: 32 · 2020: 34 · 2019: 34 · 2018: 10 · 2017: 1
FWCI
7.77
Type
journal article
Language
en
Open access
Locations
  • Acta Biomaterialia (publishedVersion)
  • PubMed (publishedVersion)
  • arXiv (Cornell University) (submittedVersion)
  • Docta Complutense (Universidad Complutense de Madrid) (submittedVersion, other-oa)
  • arXiv (Cornell University)
Funders
  • European Research Council
  • Spanish Ministerio de Economía y Competitividad
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Materials Science › Materials Chemistry › Mesoporous Materials and Catalysis
Keywords
mesoporous silica nanoparticles, doxorubicin, pH-responsive drug delivery, concanavalin A, sialic acid, osteosarcoma, targeted drug delivery, tumor cell internalization, nanomedicine
MeSH terms
Animals, Antibiotics, Antineoplastic, Bone Neoplasms, Concanavalin A, Doxorubicin, Drug Carriers, Humans, Hydrogen-Ion Concentration, Microscopy, Fluorescence, Polysaccharides, Sialic Acids, Silicon Dioxide, X-Ray Diffraction, Porosity, 3T3 Cells, Drug Delivery Systems, Spectroscopy, Fourier Transform Infrared, Lectins, Cell Line, Tumor, Microscopy, Electron, Transmission, Mice, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review